Analyst Price Target is $3.00
▲ +322.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Leap Therapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $4.00 and a low forecast of $2.50. The average price target represents a 322.77% upside from the last price of $0.71.
Current Consensus is
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Leap Therapeutics. This Buy consensus rating has held steady for over two years.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Read More